Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ryan Hall (NPI 1366761975)

Field	Value
Entity Type	Individual
Organization	Ryan Hall
Address	8901 Carti Way
City	Little Rock
State	AR
ZIP	72205
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 21, 2010

Payer Source	Total Paid
Medicare	$4.6M
Medicaid	$0

Key Findings

This provider’s commercial footprint is effectively single‑payer: total Medicare revenue is $4.6M and there is no Medicaid billing on file, indicating the practice’s public‑payer exposure is concentrated in Medicare beneficiaries rather than a mixed Medicare/Medicaid panel. That concentration creates operational dependence on Medicare reimbursement and case mix rather than on dual‑payer flows.

Revenue is highly concentrated in a small set of high‑cost oncology drugs: the precomputed top three Medicare codes account for 64.5% of the provider’s Medicare revenue, driven by J9271 ($1.4M revenue, 33.1% of this provider's total Medicare revenue), J9299 ($888.5K revenue, 20.6% of this provider's total Medicare revenue), and J9173 ($466K revenue, 10.8% of this provider's total Medicare revenue). This concentration implies that price or utilization changes for a handful of immunotherapy agents would have outsized effects on practice revenue.

The CPT/HCPCS mix shows an infusion‑centric oncology practice: dominant drugs are immunotherapies (J9271, J9299, J9173, J9022) alongside supportive and chemotherapy agents such as J0897 (denosumab), J2506 (pegfilgrastim), and J0885 (epoetin alfa). Combined with high volumes of chemo administration codes (96413, 96375, 96417), the data are consistent with an office or infusion center that primarily administers systemic cancer therapies and provides associated supportive care.

Competitive standing on key biologics is above typical national volume for several agents: J9271 (pembrolizumab) ranks #86 of 1841 providers nationally at the 95th percentile and is described as "notably above typical national volume," while J9299 (nivolumab) ranks #41 of 505 providers at the 92th percentile and is also "notably above typical national volume." By contrast, J9173 (durvalumab) ranks #9 of 53 providers at the 85th percentile and is labeled "typical, unremarkable volume," indicating strong national presence for some immunotherapies but more conventional participation in others.

Multiple administration and E/M codes are statistical outliers, signaling high treatment throughput and frequent patient encounters: 96413 ($97.7K, 2.3% of Medicare revenue) is a 99th‑percentile "extreme outlier, far above typical national volume," 96375 ($19.6K, 0.5%) is also a 99th‑percentile "extreme outlier," and 96417 ($15.9K, 0.4%) is a 99th‑percentile "extreme outlier." These flags indicate unusually high chemotherapy/infusion procedure volumes relative to national peers and reinforce the interpretation of a high‑throughput infusion operation.

Office evaluation and management plus onsite labs support an integrated ambulatory oncology workflow: 99214 accounted for $102.9K (2.4% of Medicare revenue) and is ranked as a 98th‑percentile "extreme outlier, far above typical national volume," and lab codes 80053, 85025 and specimen collection 36415 are all in very high national percentiles. Together these findings suggest the provider conducts frequent, higher‑complexity follow‑up visits and performs or orders routine lab monitoring within the practice setting.

Biosimilars and supportive biologics appear in the mix but at modest shares relative to the top immunotherapies: Q5126 (bevacizumab biosimilar) generated $116K (2.7% of Medicare revenue) but ranks at the 32th percentile nationally, and Q5115 (rituximab biosimilar) produced $72.8K (1.7%) and ranks at the 35th percentile. This pattern suggests some use of biosimilars and biologic alternatives but not yet a dominant biosimilar strategy versus peers.

The provider has an established billing history with NPI enumeration on 2010-05-21 (~16 years ago), which, combined with concentrated Medicare revenue and high infusion volumes, points to a mature, specialty oncology practice that relies on recurrent systemic therapy administration. Given the lack of Medicaid billing on file, strategic or financial shifts that affect Medicare oncology payments or utilization of high‑cost immunotherapies would likely have immediate material impact on this practice’s revenue profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

114 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	33,200	$40	$1.4M
J9299	Injection, nivolumab, 1 mg	37,020	$20	$888.5K
J9173	Injection, durvalumab, 10 mg	7,640	$60	$466K
J9022	Injection, atezolizumab, 10 mg	4,940	$60	$316.4K
J0897	Injection, denosumab, 1 mg	13,680	$20	$246.2K
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	2,230	$50	$116K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	11,200	$10	$112K
J1437	Injection, ferric derisomaltose, 10 mg	6,800	$20	$108.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,180	$90	$102.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,140	$90	$97.7K

Showing 1–10 of 114

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 114 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Ryan Hall — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

114 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	40	20,700	$40	$896.3K
J9299	2	30	15,660	$20	$432.9K
J9022	2	10	4,940	$60	$407.4K
J9173	1	10	5,110	$60	$310.2K
Q5126	5	10	3,210	$60	$174.1K
J1569	11	10	2,560	$40	$120.3K
J1437	12	20	6,450	$20	$107.8K
J9264	3	10	9,300	$10	$96.2K
Q5115	17	20	2,800	$30	$95.9K
J0897	14	160	2,580	$20	$89.7K

Showing 1–10 of 114

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ryan Hall, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Central Arkansas Radiation Therapy Institute Inc	AR	Hematology & Oncology Physician	$0	$11M
Central Arkansas Radiation Therapy Institute Inc	AR	Radiation Oncology Physician	$6.7M	$3.6M
Kamal Patel	AR	Hematology & Oncology Physician	$5.7M	$0
Balagopalan Nair	AR	Hematology & Oncology Physician	$4.1M	$0
Lawrence Mendelsohn	AR	Hematology & Oncology Physician	$3.4M	$0
Jamie Burton	AR	Hematology & Oncology Physician	$2.8M	$0
Kewen Jauss	AR	Hematology & Oncology Physician	$2.8M	$0
Mariann Harrington	AR	Hematology & Oncology Physician	$2.7M	$0
Appalanaidu Sasapu	AR	Hematology & Oncology Physician	$2.6M	$0
Derek Middleton	AR	Hematology & Oncology Physician	$2.5M	$0

Nearby Providers

Other providers in the same ZIP code as Ryan Hall, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
University Of Arkansas For Medical Sciences	AR	General Acute Care Hospital	$0	$87.2M
University Of Arkansas For Medical Sciences	AR	Internal Medicine Physician	$0	$28.6M
University Of Arkansas For Medical Sciences	AR	Pediatrics Physician	$0	$27.6M
Arkansas Department Of Health Immunizations	AR	Public Health or Welfare Agency	$0	$19.3M
Baptist Health	AR	General Acute Care Hospital	$0	$16.4M
Arkansas Department Of Health Family Planning Clinic	AR	Public Health or Welfare Agency	$0	$15.6M
Pediatrix Medical Group Of Arkansas PA	AR	Neonatal-Perinatal Medicine Physician	$0	$14.6M
Chenal Family Therapy, Plc	AR	Mental Health Counselor	$0	$12.2M
Francis A. Allen School For Exceptional Children, Inc.	AR	Developmentally Disabled Services Day Training Agency	$0	$11.9M
Arkansas Department Of Health Std	AR	Public Health or Welfare Agency	$0	$8.4M

Ryan Hall — Billing Profile & Reimbursement Data

Sign up for Ryan Hall — Billing Profile & Reimbursement Data policy alerts

Ryan Hall — Billing Profile & Reimbursement Data

Sign up for Ryan Hall — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References